伟德官网手机版附屬鼓樓醫院血液内科副主任醫師，副教授，博士生導師，醫藥生物技術國家重點實驗室PI。

主要研究方向包括：1、血小闆、幹細胞等活細胞診療技術研發與轉化；2、惡性血液病的複發機制及幹預；3、基于人工智能的血液病個體化診療新方法。

本人近年來圍繞血液腫瘤的生物治療開展研究，共發表SCI論文89篇，其中作為第一或通訊作者在Nat Commun, Cell Death Differ, Adv Funct Mater等高影響力期刊發表文章共56篇；參與編寫血液學英文專著1部、中文專著1部；主持包括三項國家自然科學基金等項目十餘項，目前在研課題包括1項國家級面上項目和1項國家重點研發計劃子課題，可支配經費300餘萬元；申請專利13項（授權11項），1 項研究成果獲得南京轉化研究院重點培育項目進入孵化階段（2020），牽頭研究者發起的臨床試驗2項，研究成果被Nature、頂級專業期刊Blood及國際著名科技媒體NanoTech等大幅引用及高度評價。

1.      中華醫學會血液學分會青年委員會，委員

2.      江蘇省醫學會血液學分會青年委員會，副主任委員

3.      江蘇省研究型醫院協會漿細胞病專委會，委員兼秘書長

4.      江蘇省醫師協會遺傳分會，委員

5.        南京市醫學會血液學分會青年委員會，副主任委員

1.      Overcoming Hypoxia by Multistage Nano Delivery System to Inhibit Mitochondrial Respiration for Photodynamic Therapy. Advanced functional materials, 2019, 29, 1807294 IF=18.808

2.      ailoring the component of protein corona via simple chemistry,Nature Communication, 2019,10, 4520 IF=14.919

3.      Licochalcone A suppresses Sp1 expression with potential anti-myeloma activity. Cancer Commun (Lond). 2021,19 IF=10.392

4.      Doxorubicin-loaded platelets as a smart drug delivery system: An improved therapy for lymphoma. Sci Rep, 2017, 7, 42632 IF=5.379

5.      Ultrafast glucose-responsive, high loading capacity erythrocyte to self-regulate the release of insulin. Acta Biomaterialia, 2018, 69, 301-312 IF=10.947

6.      Platinum prodrug inhibiting tumor recurrence and metastasis by  concurrent chemo radiotherapy. Journal of Nanobiotechnology.(2022) 20:129. IF=10.509

7.      Anti-Fas Antibody Conjugated Nanoparticles Enhancing the Antitumor Effect of Camptothecin by Activating the Fas−FasL Apoptotic Pathway.ACS Appl Mater Inter. 2016;8(44):29950-29959. IF=10.383

8.      Screening T‑Cell Activity via a Photodetachable DNA-Copolymer Nanocage and Its Therapeutic Application.Analytical Chemistry.2022,94, 38, 13205-13214. IF=8.808

9.      Overcoming the blood-brain barrier by using a multistage platelet delivery system to inhibit central nervous system lymphoma. Nanomedicine: Nanotechnology, Biology and Medicine.2022,01,15499634. IF=8.458

10.   Ultrafast glucose-responsive, high loading capacity erythrocyte to self-regulate the release of insulin. Acta Biomaterialia, 2018, 69, 301- 312 IF=8.947

11.   PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma, Cell Death Disease. 2021,16;12(10):851 IF=8.469

12.   Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL. Mol Ther Oncolytics. 2021,28;23:96-106 IF=7.200

13.   Vincristine-Loaded Platelets Coated with Anti-CD41 MAbs: A New Proposal for the Treatment of Immune Thrombocytopenia. Biomater Science, 2019, 7, 4568-4577 IF=6.843

14.   Nitroxide-radicals-modified gold nanorods for in vivo CT/MRI-guided photothermal cancer therapy. Int J Nanomedicine. 2018, 13, 7123-7134 IF=6.4

15.   Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment. Int J Nanomedicine. 2020, 15, 521-536 IF=6.4

16.   Acetazolamide-Loaded pH-Responsive Nanoparticles Alleviating Tumor Acidosis to Enhance Chemotherapy Effects. Macromolecular Bioscience, 2019, 19(2): 11 IF=4.979

17.   Gene signatures and prognostic values of m6A-related genes in multiple myeloma. Curr Res Transl Med. 2021;69(2):103288 IF=4.513

18.   Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma,Cancer Med,2021;10(20):7395-7403 IF=4.45

19.   Doxorubicin-loaded platelets as a smart drug delivery system: An improved therapy for lymphoma. Sci Rep, 2017, 7, 42632 IF=4.379

20.   Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors. Oncotargets and Therapy, 2017, 10: 4731-4738 IF=4.147

21.   A centromere-associated gene score for rapid determination of risk in multiple myeloma. American Journal of Translational Research. 2020, 12, 2425-2438 IF=4.060

22.   Bortezomib activation of mTORC1 pathway mediated by NOX2-drived reactive oxygen species results in apoptosis in primary dorsal root ganglion neurons. Experimental Cell Research.2021;400(2):112494 IF=3.905

23.   Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma. Clinica Chimica Acta, 2018, 481, 34-41 IF=3.786

24.   PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma. Biomed Res Int, 2020, 4286101 IF=3.411

25.   Expression of MAGE-C1/CT7 provides prognostic information in multiple myeloma. Leukemia & Lymphoma, 2017, 58(1): 244-246 IF=3.28

26.   MiR-181a enhances drug sensitivity of mixed lineage leukemia- rearranged acute myeloid leukemia by increasing poly(ADP-ribose) polymerase1 acetylation. Leuk Lymphoma. 2021;62(1):136-146 IF=3.28

27.   Effects of digoxin on cell cycle, apoptosis and NF-kappa B pathway in Burkitt's lymphoma cells and animal model. Leukemia & Lymphoma, 2017, 58(7): 1673-1685 IF=3.28

28.   TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis. Plos One, 2017, 12(4): 14 IF=3.24

29.   Anti-CD22-conjugated CdTe QDs co-loaded with doxorubicin and gambogic acid: a novel platform for lymphoma treatment. Rsc Advances, 2017, 7(54): 33905-33913 IF=3.119

30.   Correlation of miR- 181a and three HOXA genes as useful biomarkers in acute myeloid leukemia. Int J Lab Hematol, 2020, 42, 16-22 IF=2.877

31.   Wogonin Inhibits Growth of Mantle Cell Lymphoma Cells, through Nuclear Factor-κB Signaling Pathway. Chin Med J, 2018, 4, 495-497 IF=2.628

32.   Development of follicular lymphoma after treatment of diffuse large B- cell lymphoma: two case reports with review of literature. International Journal of Experimental Pathology. 2018, 11, 324-332 IF=1.925

33.   Successful management of a complicated clinical crisis: A patient with left- sided endocarditis and secondary hemophagocytic lymphohistiocytosis: a rare case report and literature review. Medicine, 2017, 96(51): 5 IF=1.84

34.   Doxorubicin-Loaded CuS Nanoparticles Conjugated with GFLG: A Novel Drug Delivery System for Lymphoma Treatment. Nano, 2019, 14(1):11 IF=1.566

35.   ,Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma. Translational Cancer Research, 2019, 8(5): 2099-2106 IF=1.214

36.   Refractory multiple myeloma with extramedullary plasmacytoma of the spleen and suspicious teratoma: a rare case report and literature review. Int J Clin Exp Pathol. 2021,15;14(4):455-462 IF=0.805

1.      基于新型“CAR-血小闆載藥體系”的噬血細胞綜合征免疫靶向治療及機制研究，國家自然基金面上項目

2.      生物活體功能材料的疾病治療應用，國家重點研發計劃子課題

3.      激活休眠骨髓瘤細胞的作用及其機制研究，中央高校原創與交叉研究基金培育項目

4.      “333高層次人才”（第五期），江蘇省人社廳

5.      可靶、可視、可控的外泌體載藥體系的設計及其抗中樞淋巴瘤效應研究，南京市重點項目

6.      全反式維甲酸聯合潑尼松對照潑尼松治療初發/初治ITP的前瞻性、單中心、随機、對照臨床研究，南京鼓樓醫院臨床研究專項資金項目

7.      基于深度學習的顯微高光譜圖像血液腫瘤組織分類，華東師範大學上海市多維度信息處理重點實驗室合作項目

1.      CD22-血小闆-DOX靶向載藥系統的構建及其抗腫瘤效應研究，中華醫學會第十六次全國血栓與止血會議“優秀大會發言”，二等獎，2017年

2.      中華醫學會第十七次會議全國血栓與止血學術會議最佳論文獎，2019年

3.      血小闆載化療藥物治療惡性腫瘤的研究，江蘇腫瘤醫學科學技術獎，一等獎，2017年

4.      基于免疫識别的靶向血小闆載藥體系在血液腫瘤的應用，省部級最佳論文獎，一等獎，2019年

5.      基于人工智能的惡性血液病個體化診療策略體系構建與實施，省部級醫學新技術引進獎，一等獎，2020年

6.      強心甾類固醇及納米技術治療淋巴系統腫瘤的基礎及臨床轉化研究，南京市科學技術進步獎，三等獎，2017年